Kumpulan Info tentang,
UNIVERSITAS SURABAYA
| No | Source Title | CiteScore | Quartile | Publisher | Highest percentile | Citations 2021-24 | Documents 2021-24 |
|---|---|---|---|---|---|---|---|
| 7141 | Expert Review of Anticancer Therapy | 5.2 | Q2 | Taylor & Francis | 65.0% 95/275 Pharmacology (medical) | 2366 | 453 |
| 7142 | Journal of Clinical Pharmacology | 5.1 | Q2 | John Wiley & Sons | 64.0% 98/275 Pharmacology (medical) | 3261 | 641 |
| 7143 | Primary Care - Clinics in Office Practice | 5.1 | Q2 | Elsevier | 64.0% 97/275 Pharmacology (medical) | 1020 | 200 |
| 7144 | Journal of Ocular Pharmacology and Therapeutics | 3.5 | Q2 | Mary Ann Liebert | 63.0% 52/141 Ophthalmology | 1036 | 295 |
| 7145 | International Clinical Psychopharmacology | 4.6 | Q2 | Wolters Kluwer Health | 63.0% 210/580 Psychiatry and Mental Health | 836 | 181 |
| 7146 | Expert Review of Pharmacoeconomics and Outcomes Research | 3.8 | Q2 | Taylor & Francis | 62.0% 120/320 Health Policy | 1626 | 431 |
| 7147 | Expert Opinion on Emerging Drugs | 4.7 | Q2 | Taylor & Francis | 62.0% 105/275 Pharmacology (medical) | 545 | 115 |
| 7148 | Journal of Clinical Pharmacy and Therapeutics | 4.8 | Q2 | John Wiley & Sons | 62.0% 104/275 Pharmacology (medical) | 2796 | 586 |
| 7149 | Journal of Clinical Psychopharmacology | 4.3 | Q2 | Wolters Kluwer Health | 61.0% 225/580 Psychiatry and Mental Health | 1253 | 290 |
| 7150 | Therapeutic Drug Monitoring | 4.7 | Q2 | Wolters Kluwer Health | 61.0% 106/275 Pharmacology (medical) | 1849 | 391 |
| 7151 | European Journal of Contraception and Reproductive Health Care | 3.7 | Q2 | Taylor & Francis | 60.0% 83/210 Obstetrics and Gynecology | 813 | 222 |
| 7152 | Clinical Psychopharmacology and Neuroscience | 4.3 | Q2 | Korean College of Neuropsychopharmacology | 60.0% 228/580 Psychiatry and Mental Health | 1303 | 303 |
| 7153 | PharmaNutrition | 4.2 | Q2 | Elsevier | 60.0% 159/404 Food Science | 516 | 123 |
| 7154 | Research Results in Biomedicine | 1.9 | Q2 | Belgorod State National Research University | 59.0% 19/46 Pharmacology, Toxicology and Pharmaceutics (miscellaneous) | 302 | 160 |
| 7155 | American Journal of Therapeutics | 4.6 | Q2 | Wolters Kluwer Health | 59.0% 112/275 Pharmacology (medical) | 901 | 195 |
| 7156 | Drugs of Today | 4.6 | Q2 | Clarivate | 59.0% 111/275 Pharmacology (medical) | 542 | 117 |
| 7157 | Human Psychopharmacology | 4 | Q2 | John Wiley & Sons | 58.0% 241/580 Psychiatry and Mental Health | 506 | 127 |
| 7158 | Clinica e Investigacion en Arteriosclerosis | 3.7 | Q2 | Sociedad Espanola de Arteriosclerosis | 58.0% 167/397 Cardiology and Cardiovascular Medicine | 692 | 188 |
| 7159 | Expert Opinion on Pharmacotherapy | 4.6 | Q2 | Taylor & Francis | 58.0% 114/275 Pharmacology (medical) | 3399 | 743 |
| 7160 | Biopharmaceutics and Drug Disposition | 4.4 | Q2 | John Wiley & Sons | 57.0% 117/275 Pharmacology (medical) | 505 | 114 |
| 7161 | Hospital Pharmacy | 1.8 | Q2 | Thomas Land Publishers Inc. | 56.0% 21/47 Pharmacy | 688 | 391 |
| 7162 | Cardiology (Switzerland) | 3.5 | Q2 | Karger | 56.0% 173/397 Cardiology and Cardiovascular Medicine | 977 | 276 |
| 7163 | Journal of Infection and Chemotherapy | 4.3 | Q2 | Elsevier | 56.0% 120/275 Pharmacology (medical) | 4523 | 1051 |
| 7164 | Pharmacoepidemiology and Drug Safety | 3.7 | Q2 | John Wiley & Sons | 55.0% 71/158 Epidemiology | 2464 | 664 |
| 7165 | Current Cardiovascular Risk Reports | 4.2 | Q2 | Springer Nature | 55.0% 123/275 Pharmacology (medical) | 368 | 87 |
| 7166 | Clinical Pharmacology in Drug Development | 3.8 | Q2 | John Wiley & Sons | 54.0% 84/185 Pharmaceutical Science | 2092 | 551 |
| 7167 | Journal of Pharmacy Practice and Research | 1.7 | Q2 | John Wiley & Sons | 54.0% 22/47 Pharmacy | 310 | 182 |
| 7168 | Anti-Cancer Drugs | 4.1 | Q2 | Wolters Kluwer Health | 54.0% 127/275 Pharmacology (medical) | 2632 | 644 |
| 7169 | European Journal of Drug Metabolism and Pharmacokinetics | 4.2 | Q2 | Springer Nature | 54.0% 125/275 Pharmacology (medical) | 1031 | 248 |
| 7170 | Journal of Aerosol Medicine and Pulmonary Drug Delivery | 3.6 | Q2 | Mary Ann Liebert | 53.0% 86/185 Pharmaceutical Science | 489 | 136 |